Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas

Authors

Eugene I. Hwang, George Washington UniversityFollow
Regina I. Jakacki, Children's National Medical Center, Washington, DC
Michael J. Fisher, Children's Hospital of Pittsburgh,
Lindsay B. Kilburn, Children's Hospital of Philadelphia
Marianna Horn, Children's Center for Cancer and Blood Disorders of Northern Virginia, Falls Church, VA,
Gilbert Vezina, George Washington UniversityFollow
Brian R. Rood, George Washington UniversityFollow
Roger J. Packer, Children's National Medical Center, Washington, DCFollow

Document Type

Journal Article

Publication Date

5-2013

Journal

Pediatric Blood and Cancer

Volume

Volume 60, Issue 5

Inclusive Pages

776-782

Keywords

Antibodies; Monoclonal; Humanized--adverse effects; Antibodies; Monoclona; Humanized--therapeutic use; Brain Neoplasms--drug therapy; Glioma--drug therapy; Neoplasm Recurrence; Local--drug therapy

APA Citation

Hwang, E. I., Jakacki, R. I., Fisher, M. J., Kilburn, L. B., Horn, M., Vezina, G., Rood, B.R., Packer, R. J. (2013). Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatric Blood and Cancer, 60(5), 776-782.

Peer Reviewed

1